Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Synergy between l-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: Implications for Parkinson's disease treatment and dyskinesia
Khaled-Ezaheir Bennouar, Michelle A. Uberti, Christophe Melon, et al.
Neuropharmacology (2012) Vol. 66, pp. 158-169
Closed Access | Times Cited: 94

Showing 1-25 of 94 citing articles:

Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
Matthieu F. Bastide, Wassilios G. Meissner, Barbara Picconi, et al.
Progress in Neurobiology (2015) Vol. 132, pp. 96-168
Open Access | Times Cited: 429
Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders
P. Jeffrey Conn, Craig W. Lindsley, Jens Meiler, et al.
Nature Reviews Drug Discovery (2014) Vol. 13, Iss. 9, pp. 692-708
Open Access | Times Cited: 241
Metabotropic glutamate receptors and neurodegenerative diseases
Fabíola M. Ribeiro, Luciene Bruno Vieira, Rita Gomes Wanderley Pires, et al.
Pharmacological Research (2016) Vol. 115, pp. 179-191
Closed Access | Times Cited: 230
Development of allosteric modulators of GPCRs for treatment of CNS disorders
Hilary Highfield Nickols, P. Jeffrey Conn
Neurobiology of Disease (2013) Vol. 61, pp. 55-71
Open Access | Times Cited: 216
Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors
Craig W. Lindsley, Kyle A. Emmitte, Corey R. Hopkins, et al.
Chemical Reviews (2016) Vol. 116, Iss. 11, pp. 6707-6741
Open Access | Times Cited: 166
Roles of Glutamate Receptors in Parkinson’s Disease
Zhu Zhang, Shiqing Zhang, Pengfei Fu, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 18, pp. 4391-4391
Open Access | Times Cited: 140
Targeting metabotropic glutamate receptors for novel treatments of schizophrenia
James Maksymetz, Sean P. Moran, P. Jeffrey Conn
Molecular Brain (2017) Vol. 10, Iss. 1
Open Access | Times Cited: 122
Selective Actions of Novel Allosteric Modulators Reveal Functional Heteromers of Metabotropic Glutamate Receptors in the CNS
Yin Shen, Meredith J. Noetzel, Kari A. Johnson, et al.
Journal of Neuroscience (2013) Vol. 34, Iss. 1, pp. 79-94
Open Access | Times Cited: 119
Non-dopaminergic approaches to the treatment of motor complications in Parkinson's disease
M. Angela Cenci, Katrine Skovgård, Per Odin
Neuropharmacology (2022) Vol. 210, pp. 109027-109027
Closed Access | Times Cited: 39
Old and new challenges in Parkinson's disease therapeutics
Ana O. Pires, Fábio G. Teixeira, Bárbara Mendes-Pinheiro, et al.
Progress in Neurobiology (2017) Vol. 156, pp. 69-89
Open Access | Times Cited: 79
Metabotropic glutamate receptors as therapeutic targets in Parkinson's disease: An update from the last 5 years of research
Nadhir Litim, Marc Morissette, Thérèse Di Paolo
Neuropharmacology (2016) Vol. 115, pp. 166-179
Closed Access | Times Cited: 78
The impact of metabotropic glutamate receptors into active neurodegenerative processes: A “dark side” in the development of new symptomatic treatments for neurologic and psychiatric disorders
Valeria Bruno, Filippo Caraci, Agata Copani, et al.
Neuropharmacology (2016) Vol. 115, pp. 180-192
Closed Access | Times Cited: 67
mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia
Irene Sebastianutto, M. Angela Cenci
Current Opinion in Pharmacology (2018) Vol. 38, pp. 81-89
Closed Access | Times Cited: 64
Haloperidol‐induced catalepsy as an animal model for parkinsonism: A systematic review of experimental studies
Isabelle Waku, Mylena S. Magalhães, Camila de Oliveira Alves, et al.
European Journal of Neuroscience (2021) Vol. 53, Iss. 11, pp. 3743-3767
Closed Access | Times Cited: 47
Targeting Glutamate Receptors to Tackle the Pathogenesis, Clinical Symptoms and Levodopa-Induced Dyskinesia Associated with Parkinson’s Disease
Susan Duty
CNS Drugs (2012) Vol. 26, Iss. 12, pp. 1017-1032
Closed Access | Times Cited: 70
Group III and subtype 4 metabotropic glutamate receptor agonists: Discovery and pathophysiological applications in Parkinson's disease
Marianne Amalric, S. Lopez, Cyril Goudet, et al.
Neuropharmacology (2012) Vol. 66, pp. 53-64
Closed Access | Times Cited: 68
Identification of Positive Allosteric Modulators VU0155094 (ML397) and VU0422288 (ML396) Reveals New Insights into the Biology of Metabotropic Glutamate Receptor 7
Nidhi Jalan‐Sakrikar, Julie R. Field, Rebecca Klar, et al.
ACS Chemical Neuroscience (2014) Vol. 5, Iss. 12, pp. 1221-1237
Open Access | Times Cited: 58
Group III Metabotropic Glutamate Receptors: Pharmacology, Physiology and Therapeutic Potential
Marion Mercier, David Lodge
Neurochemical Research (2014) Vol. 39, Iss. 10, pp. 1876-1894
Closed Access | Times Cited: 56
Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers
Colleen M. Niswender, Carrie K. Jones, Xin Lin, et al.
ACS Chemical Neuroscience (2016) Vol. 7, Iss. 9, pp. 1201-1211
Open Access | Times Cited: 56
Targeting metabotropic glutamate receptors (mGluRs) in Parkinson's disease
Marianne Amalric
Current Opinion in Pharmacology (2014) Vol. 20, pp. 29-34
Closed Access | Times Cited: 52
An mGlu4‐Positive Allosteric Modulator Alleviates Parkinsonism in Primates
Delphine Charvin, Thérèse Di Paolo, Erwan Bézard, et al.
Movement Disorders (2018) Vol. 33, Iss. 10, pp. 1619-1631
Closed Access | Times Cited: 50
Ion Channels and Metal Ions in Parkinson’s Disease: Historical Perspective to the Current Scenario
Bhupesh Vaidya, Dibya S. Padhy, H.C. Joshi, et al.
Methods in molecular biology (2024), pp. 529-557
Closed Access | Times Cited: 5
Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and l-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist
Hanna Iderberg, Natallia Maslava, Analisa D. Thompson, et al.
Neuropharmacology (2015) Vol. 95, pp. 121-129
Open Access | Times Cited: 49
Pharmacology of Metabotropic Glutamate Receptor Allosteric Modulators
Karen J. Gregory, Meredith J. Noetzel, Colleen M. Niswender
Progress in molecular biology and translational science (2013), pp. 61-121
Closed Access | Times Cited: 46
The antipsychotic‐like effects of positive allosteric modulators of metabotropic glutamate mGlu4 receptors in rodents
Anna Sławińska, Joanna M. Wierońska, Katarzyna Stachowicz, et al.
British Journal of Pharmacology (2013) Vol. 169, Iss. 8, pp. 1824-1839
Open Access | Times Cited: 45
Page 1 - Next Page

Scroll to top